Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 01, 2026 16:05 ET | Source: Abivax

Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis

Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis At Week 44, both the 25 mg and 50 mg once-daily obefazimod...
June 01, 2026 16:05 ET | Source: Abivax

Abivax annonce des résultats majeurs de l’essai de maintenance de phase 3 ABTECT évaluant l’obéfazimod dans le traitement de la rectocolite hémorragique active modérée à sévère

Abivax annonce des résultats majeurs de l’essai de maintenance de phase 3 ABTECT évaluant l’obéfazimod dans le traitement de la rectocolite hémorragique active modérée à sévère À la semaine 44, les...
April 02, 2026 11:00 ET | Source: Crohn's and Colitis Canada

AbbVie IBD Scholarship Program Marks 15 Years: Applications Open for 2026

Crohn’s and Colitis Canada and AbbVie open applications for the 2026 AbbVie IBD Scholarship, marking 15 years of supporting students living with IBD.
April 02, 2026 11:00 ET | Source: Crohn's and Colitis Canada

Le programme de bourses d'études MII d’AbbVie fête ses 15 ans : les candidatures sont ouvertes pour 2026

TORONTO, 02 avr. 2026 (GLOBE NEWSWIRE) -- Crohn et Colite Canada et AbbVie sont heureux d'annoncer l'ouverture des candidatures pour le Programme de bourses d'études MII d’AbbVie 2026. Cette année...
March 03, 2026 09:16 ET | Source: Mount Sinai Press Office

Mount Sinai and King Saud University Medical City Forge a Three-Year Collaboration to Advance Precision Medicine in Familial Inflammatory Bowel Disease

New York, March 03, 2026 (GLOBE NEWSWIRE) -- [New York, NY, and Riyadh, Saudi Arabia [March 3, 2026] — Mount Sinai and King Saud University Medical City in Riyadh, Saudi Arabia, today announced a...
February 21, 2026 06:00 ET | Source: Abivax

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026 22 abstracts presented at...
December 17, 2025 16:05 ET | Source: Abivax

Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings

Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings Breadth of...
December 10, 2025 14:55 ET | Source: Allsup

Allsup Helps Individuals With Crohn’s Disease And Ulcerative Colitis Overcome Barriers To SSDI Benefits

Belleville, Illinois, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Allsup, a leading provider of Social Security Disability Insurance (SSDI) representation, return to work and veterans disability appeals...
November 13, 2025 05:00 ET | Source: Numab Therapeutics AG

Numab Therapeutics and Kaken Pharmaceutical Announce Licensing and Co-development Agreement for Multispecific Antibody NM81 in Inflammatory Bowel Disease (IBD)

HORGEN, Switzerland and TOKYO, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Numab Therapeutics AG (“Numab”), a biotechnology company advancing a proprietary pipeline of multispecific antibodies in immunology...
November 12, 2025 05:00 ET | Source: Yaqrit

First patient dosed in a proof-of-concept study of Yaqrit’s advanced microbiome therapeutic YAQ001 in patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Disease

Yaqrit progresses novel treatment into pilot study for primary sclerosing cholangitis and IBD. Results expected H2 2026